

Milano 10 Agosto 2016

Curriculum Vitae del Dott. Fedro Alessandro Peccatori

INFORMAZIONI PERSONALI

COGNOME	PECCATORI
NOME	FEDRO ALESSANDRO
DATA DI NASCITA	16 Marzo 1963
CF	PCCFRL63C16F205S

Cittadinanza Italiana

Felicitemente coniugato con Giulia dal 1990, 5 figli Nicolò, Elisa, Federico, Tommaso, Francesco

Lingue: Italiano (lingua madre), Inglese (ottimo livello scritto e parlato), Francese (buona comprensione)

Spagnolo (buona comprensione)

Recapiti lavorativi

Istituto Europeo di Oncologia

Fertility and Procreation Unit

Gynecologic Oncology Division

Via Ripamonti 435, 20141 Milan, Italy

Tel +39 0257489543-685

Cell +393498357703

Fax +390294379222 fedro.peccatori@ieo.it

European School of Oncology

Via Turati 29, 20121 Milan Italy

Tel +41918200956

Fax +41918200953 fpeccatori@eso.net

Percorso formativo

2014 Program Oncology Leaders in Europe (POLE), Università Bocconi, Milano

2008 Master di II livello in Sessuologia, Università di Pisa

2006 Master in Medical Management Università Cattolica, Milano

1999 Specializzazione in Oncologia Medica, Università di Milano UNIMI, 70/70 cum laude

1996 Philosophy Doctor (PhD) in Scienze Oncologiche in Ginecologia, Università Sapienza, Roma

1995 Specializzazione in Ostetricia e Ginecologia, Università di Milano UNIMI, 70/70 cum laude

1988 Laurea in Medicina Università di Milano UNIMI, 110/110 cum laude

1982 Maturità Classica Liceo C Beccaria, Milano 58/60

1980 High School Graduation Ladue High School, St Louis, MO USA

Posizioni professionali

2016... *Direttore scientifico*, European School of Oncology, Milano and Bellinzona

2011... *Direttore*, Unità Fertilità e Procreazione in Oncologia, Divisione di Ginecologia Oncologica, Istituto Europeo di Oncologia IRCCS, Milano

2014-15 *Vicedirettore Scientifico*, European School of Oncology, Milano and Bellinzona

2007-11 *Direttore*, Unità Trapianto Allogeneico, Divisione di Oncoematologia, Istituto Europeo di Oncologia IRCCS, Milano

2001-07 *Vicedirettore senior*, Divisione di Oncoematologia, Istituto Europeo di Oncologia IRCCS, Milano

1998-01 *Vicedirettore*, Divisione di Oncoematologia, Istituto Europeo di Oncologia IRCCS, Milano

1995-98	<i>Assistente</i> , Divisione di Oncologia Medica e Ematoncologia Istituto Europeo di Oncologia IRCCS, Milano
1994-95	<i>Clinical fellow</i> , Department of Pathology and Gynecology Free University Hospital, AMC e European Cancer Center, Amsterdam, NL
1992-93	<i>Fellow</i> , Divisione di Oncologia Medica Unità di Trapianto Midollo Osseo Cristina Gandini, Istituto Nazionale Tumori, Milano
1991-92	<i>Assistente</i> , Divisione di Oncologia Medica Ospedale San Giovanni, Servizio Oncologico Cantonale, Bellinzona, CH
1988-90	<i>Resident</i> , Divisione di Ostetricia e Ginecologia, III Clinica Università di Milano Ospedale San Gerardo, Monza
1985-89	<i>Associate Researcher</i> , Laboratorio di Immunologia Umana. Istituto di Ricerche Farmacologiche "Mario Negri", Milano

Memberships

- Full Member della American Society of Clinical Oncology (ASCO). Invited speaker ASCO 2012 "Ethical challenges in oncological patients"
- Full Member della European Society of Medical Oncology (ESMO), certified in 1996.
- Invited speaker in numerose occasioni (2014,2015, 2017) Working group, AYA (Adult and young adolescent). ESMO clinical practice guideline "Cancer, Pregnancy and Fertility"
- Full Member della Italian Association of Medical Oncology (AIOM). Autore delle AIOM guidelines "Preservazione della Fertilità in Oncologia", 2016
- Full Member della European Society of Gynecological Cancer (ESGO). Co-Chair del I Masterclass ESO/ESGO di Oncologia Ginecologica, Lund 2016
- Member di IBCSG (International Breast Cancer Study Group)
- Member di BIG (Breast International Group)
- Steering committee member Global status of mBC decade report
- Full member della European School of Oncology. Co-chair di Masterclass in Clinical Oncology, Ermatingen 2016, Invited speaker in numerose occasioni (vedi www.eso.net)
- Past president di PROFERT (Italian Society for the Preservation of Fertility) fino al 2015
- Consigliere Scientifico Associazione "Correre per la Speranza"
- Consigliere Scientifico Associazione ACTO Onlus (Associazione Contro il Tumore Ovarico)

Attività clinica e di ricerca

Fedro Peccatori è medico oncologo, specialista in Oncologia Medica e in Ostetricia e Ginecologia. La sua attività clinica include principalmente la diagnosi e il trattamento del carcinoma mammario, dei tumori maligni ginecologici e dei tumori dei giovani adulti. E' Direttore dell'Unità Fertilità e Procreazione in Oncologia presso il Programma di Ginecologia dell'Istituto Europeo di Oncologia (IEO), Milano. Ha fatto parte del Dipartimento di Medicina e Oncologia Medica fino al 2014, quando sono stati istituiti in IEO i programmi multidisciplinari per patologia ed è diventato referente Oncologo del Programma di Ginecologia. I suoi principali progetti di ricerca comprendono la preservazione della fertilità nelle pazienti oncologiche, la protezione farmacologica della funzione ovarica durante chemioterapia, la caratterizzazione molecolare e clinica dei tumori mammari diagnosticati in gravidanza e protocolli di trattamento farmacologico dei tumori della mammella e ginecologici. In passato si è interessato di ricerca e cura delle neoplasie ematologiche, del trattamento dei linfomi maligni e di trapianto di cellule staminali periferiche autologhe e allogeniche nei tumori solidi e leucemie. E' stato responsabile insieme alla dottoressa Cristiana Sessa del progetto "Nuovi Farmaci" all'Istituto Europeo di Oncologia nel 1997, stabilendo le connessioni internazionali attraverso SENDO (Southern Europe New Drug Organization), di cui era membro, che hanno poi portato alla implementazione della Unità e successivamente della Divisione Nuovi Farmaci. Come ex presidente di PROFERT ha contribuito a costruire la rete italiana di conservazione della fertilità per i pazienti affetti da cancro. E' Direttore Scientifico della European School of Oncology (ESO), dove è incaricato di organizzare e corsi internazionali e masterclass su diversi problemi oncologici.

Attività didattica

Ha partecipato con continuità da relatore, curatore o chair in eventi scientifici nazionali e internazionali per lo più su temi relativi al trattamento del cancro della mammella in donne giovani o alle problematiche di fertilità e gravidanza nelle pazienti oncologiche (elenco disponibile a richiesta).

Ha insegnato alla Università d Varese, Pavia e Milano come esperto di carcinoma mammario in gravidanza in master di I e II livello e nelle scuole di Specialità di Oncologia o Endocrinologia. E' stato correlatore per tesi di laurea in Medicina e Chirurgia e Scienze infermieristiche e tesi di specialità in Ostetricia e Ginecologia.

Abilitazione nazionale a Professore di II fascia

E' stato considerato idoneo alla abilitazione nazionale del 2012 per Professore Associato di Oncologia (MED 06) e in Ostetricia e Ginecologia (MED40), ai sensi dell'art. 16 della Legge 240/2010 con giudizio positivo unanime delle commissioni in entrambi i settori scientifico disciplinari.

Grant e assegni di ricerca

CCM 2012 Il paziente oncologico lungosopravvivate. Ridurre il rischio di complicanze riproduttive. Un modello per le pratiche assistenziali per la preservazione della fertilità. 40.000 euro

FORECEE 2015 Female cancer prediction using cervical omics to individualise screening and prevention 231.000 euro

Attività editoriale

Revisore per European Journal of Chemoprevention, Annals of Oncology, The Breast, International Journal of Gynecologic Cancer, PLOS, Lancet Oncology, e cancermedicalseience.

E' nel comitato editoriale di e cancermedicalseience, Cancerworld, Tumori e Critical Review in Oncology and Hematology.

Pubblicazioni

Fedro Peccatori è autore o co-autore di 151 pubblicazioni or lettere in riviste internazionali peer reviewed, compreso New England Journal of Medicine, Lancet Oncology, Journal of Clinical Oncology, Nature Reviews Clinical Oncology, Annals of Oncology, Breast Cancer Treatment Reviews, Breast (html i.nlm.nih.gov/pubmed/?term=peccatori+f or peccatori+a). E' stato autore o editor di più di 10 capitoli di libri e reviews disponibili a stampa. E' stato autore o editor dei libri "Cancer and Pregnancy" (2007), "Fertilità e Oncologia" (2009) "Breast Cancer, Fertility Preservation and Reproduction" (2015). Ha scritto il capitolo "Cancer and Pregnancy" in "Core Curriculum in Obstetrics and Gynecology" (2013) "Special issues in the young and pregnant patients with breast cancer" in "Cancer Consult" (2014) e "Treatment in pregnancy" in the UICC Manual of Clinical Oncology (2015).

H-INDEX

Il suo h-index, consultato su Web of Knowledge è 29, con somma totale di citazioni pari a 2958 (5 Jan 2016)

Link selezionati

<http://www.cancerworld.org/Articles/Issues/54/May-June-2013/My-World/598/My-World-Fedro-Alessandro-Peccatori-.html>

<http://www.ondaosservatorio.it/elementipagine/28/it/interviste/2733/fertilita-e-tumore-le-donne-devono-poter-pensare-al-proprio>

http://www.researchgate.net/profile/Fedro_Peccatori/

http://xoomer.virgilio.it/pgiuff/oncologiacatania/Fedro_Peccatori.pdf

Video selezionati

http://www.youtube.com/watch?v=cwT_JMc29gw

<http://www.youtube.com/watch?v=5oNij0skDRI>


<http://www.youtube.com/watch?v=FEgC5gj5Dic>
<http://www.youtube.com/watch?v=vzGLSiCWcs8>

Autorizzo l'utilizzo dei miei dati personali in accordo alla legge Italiana 196/2003

Fedo A Peccatori


This report reflects citations to source items indexed within All Databases (accessed Jan 5, 2016).

Published Items in Each Year



The latest 20 years are displayed.

Citations in Each Year



The latest 20 years are displayed.

Elenco pubblicazioni

- 1) Reproductive behaviors and risk of developing breast cancer according to tumor subtype: A systematic review and meta-analysis of epidemiological studies. Lambertini M, Santoro L, Del Mastro L, Nguyen B, Livraghi L, Ugolini D, Peccatori FA, Azim HA Jr. *Cancer Treat Rev.* 2016 Sep;49:65-76. doi: 10.1016/j.ctrv.2016.07.006. Epub 2016 Jul 29. Review.
- 2) Fertility preservation in women with borderline ovarian tumours. Mangili G, Somigliana E, Giorgione V, Martinelli F, Filippi F, Petrella MC, Candiani M, Peccatori F. *Cancer Treat Rev.* 2016 Jul 7;49:13-24. doi: 10.1016/j.ctrv.2016.06.010. [Epub ahead of print] Review.
- 3) Managing pregnancy-associated breast cancer: Is more really better? Peccatori FA, Azim HA Jr. *Breast.* 2016 Jun 29. pii: S0960-9776(16)30080-7. doi: 10.1016/j.breast.2016.06.006. [Epub ahead of print]
- 4) No Evidence for the Benefit of Gonadotropin-Releasing Hormone Agonist in Preserving Ovarian Function and Fertility in Lymphoma Survivors Treated With Chemotherapy: Final Long-Term Report of a Prospective Randomized Trial. Demeestere I, Brice P, Peccatori FA, Kentos A, Dupuis J, Zachee P, Casasnovas O, Van Den Neste E, Dechene J, De Maertelaer V, Bron D, Englert Y. *J Clin Oncol.* 2016 Aug 1;34(22):2568-74. doi: 10.1200/JCO.2015.65.8864. Epub 2016 May 23.

- 5) Sclerosing angiomatoid nodular transformation of the spleen during pregnancy: Diagnostic challenges and clinical management. Corrado G, Tabanelli V, Biffi R, Petralia G, Tinelli A, Peccatori FA. *J Obstet Gynaecol Res.* 2016 Aug;42(8):1021-5. doi: 10.1111/jog.13008. Epub 2016 Apr 14.
- 6) Second international consensus guidelines for breast cancer in young women (BCY2). Paluch-Shimon S, Pagani O, Partridge AH, Bar-Meir E, Fallowfield L, Fenlon D, Friedman E, Gelmon K, Gentilini O, Geraghty J, Harbeck N, Higgins S, Loibl S, Moser E, Peccatori F, Raanani H, Kaufman B, Cardoso F. *Breast.* 2016 Apr;26:87-99. doi: 10.1016/j.breast.2015.12.010. Epub 2016 Feb 6.
- 7) Ovarian transposition in young women and fertility sparing. Del Pup L, Salvagno F, Borini A, Trovò M, Peccatori FA. *Eur Rev Med Pharmacol Sci.* 2016;20(2):197-8.
- 8) Fertility-Sparing Options in Young Women with Cervical Cancer. Tomao F, Corrado G, Peccatori FA, Boveri S, Preti EP, Colombo N, Landoni F. *Curr Treat Options Oncol.* 2016 Jan;17(1):5. doi: 10.1007/s11864-015-0386-9015-0386-9.
- 9) Cancer and fertility preservation: international recommendations from an expert meeting. Lambertini M, Del Mastro L, Pescio MC, Andersen CY, Azim HA Jr, Peccatori FA, Costa M, Revelli A, Salvagno F, Gennari A, Ubaldi FM, La Sala GB, De Stefano C, Wallace WH, Partridge AH, Anserini P. *BMC Med.* 2016 Jan 4;14:1. doi: 10.1186/s12916-015-0545-7015-0545-7.
- 10) Reply to the letter to the editor 'Can ovarian suppression with gonadotropin releasing hormone analogs (GnRHa) preserve fertility in cancer patients?' by Rodriguez-Wallberg et al. Lambertini M, Peccatori FA, Moore HC, Del Mastro L. *Ann Oncol.* 2016 Mar;27(3):548-9. doi: 10.1093/annonc/mdv599. Epub 2015 Dec 8
- 11) Chronic lymphocytic leukaemia during pregnancy: management and thoughts. Winckler P, Vanazzi A, Bozzo M, Scarfone G, Peccatori FA. *Ecancermedicalsecience.* 2015 Nov 12;9:592. doi: 10.3332/ecancer.2015.592. eCollection 2015.
- 12) Hematologic Malignancies in Pregnancy: Management Guidelines From an International Consensus Meeting. Lishner M, Avivi I, Apperley JF, Dierickx D, Evens AM, Fumagalli M, Nulman I, Oduncu FS, Peccatori FA, Robinson S, Van Calsteren K, Vandenbroucke T, Van den Heuvel F, Amant F. *J Clin Oncol.* 2016 Feb 10;34(5):501-8. doi: 10.1200/JCO.2015.62.4445. Epub 2015 Nov 30.
- 13) Medical treatment of early stage and rare histological variants of epithelial ovarian cancer. Cont NT, Ferrero A, Peccatori FA, D'Alonzo M, Codacci-Pisanelli G, Colombo N, Biglia N. *Ecancermedicalsecience.* 2015 Oct 22;9:584. doi: 10.3332/ecancer.2015.584. eCollection 2015. Review.
- 14) Tongue cancer during pregnancy: Surgery and more, a multidisciplinary challenge. Tagliabue M, Elrefaey SH, Peccatori F, Favia G, Navach V, Pignataro L, Capaccio P, Venturino M, Tredici S, Alterio D, Mosca F, Pagni L, Scarfone G, Cossu Rocca M, Calabrese L. *Crit Rev Oncol Hematol.* 2016 Feb;98:1-11. doi: 10.1016/j.critrevonc.2015.09.006. Epub 2015 Oct 9. Review.
- 15) Pediatric Outcome after Maternal Cancer Diagnosed during Pregnancy. Amant F, Vandenbroucke T, Verheecke M, Fumagalli M, Halaska MJ, Boere I, Han S, Gziri MM, Peccatori F, Rob L, Lok C, Witteveen P, Voigt JU, Naulaers G, Vallaey L, Van den Heuvel F, Lagae L, Mertens L, Claes L, Van Calsteren K; International Network on Cancer, Infertility, and Pregnancy (INCIP). *N Engl J Med.* 2015 Nov 5;373(19):1824-34. doi: 10.1056/NEJMoa1508913. Epub 2015 Sep 28.

- 16) Special issues in fertility preservation for gynecologic malignancies. Tomao F, Peccatori F, Del Pup L, Franchi D, Zanagnolo V, Panici PB, Colombo N. *Crit Rev Oncol Hematol*. 2016 Jan;97:206-19. doi: 10.1016/j.critrevonc.2015.08.024. Epub 2015 Sep 8. Review.
- 17) Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studies. Lambertini M, Ceppi M, Poggio F, Peccatori FA, Azim HA Jr, Ugolini D, Pronzato P, Loibl S, Moore HC, Partridge AH, Bruzzi P, Del Mastro L. *Ann Oncol*. 2015 Dec;26(12):2408-19. doi: 10.1093/annonc/mdv374. Epub 2015 Sep 7. Review.
- 18) Oocyte cryopreservation beyond cancer: tools for ethical reflection. Linkeviciute A, Peccatori FA, Sanchini V, Boniolo G. *J Assist Reprod Genet*. 2015 Aug;32(8):1211-20. doi: 10.1007/s10815-015-0524-0. Epub 2015 Jul 3.
- 19) Exploring the safety of chemotherapy for treating breast cancer during pregnancy. Lambertini M, Kamal NS, Peccatori FA, Del Mastro L, Azim HA Jr. *Expert Opin Drug Saf*. 2015;14(9):1395-408. doi: 10.1517/14740338.2015.1061500. Epub 2015 Jul 3. Review.
- 20) Pregnancy following breast cancer using assisted reproduction and its effect on long-term outcome. Goldrat O, Kroman N, Peccatori FA, Cordoba O, Pistilli B, Lidegaard O, Demeestere I, Azim HA Jr. *Eur J Cancer*. 2015 Aug;51(12):1490-6. doi: 10.1016/j.ejca.2015.05.007. Epub 2015 Jun 9.
- 21) Ovarian protection during adjuvant chemotherapy. Peccatori FA. *N Engl J Med*. 2015 Jun 4;372(23):2268. doi: 10.1056/NEJMc1504241#SA1. No abstract available.
- 22) Attitudes on fertility issues in breast cancer patients: an Italian survey. Biglia N, Torrasi R, D'Alonzo M, Codacci Pisanelli G, Rota S, Peccatori FA. *Gynecol Endocrinol*. 2015 Jun;31(6):458-64. doi: 10.3109/09513590.2014.1003293. Epub 2015 May 18.
- 23) Risk factors: After gestational chemotherapy, the kids are all right. Peccatori FA, Corrado G, Fumagalli M. *Nat Rev Clin Oncol*. 2015 May;12(5):254-5. doi: 10.1038/nrclinonc.2015.66. Epub 2015 Apr 14. No abstract available.
- 24) Difficult choices for young patients with cancer: the supportive role of decisional counseling. Chiavari L, Gandini S, Feroce I, Guerrieri-Gonzaga A, Russell-Edu W, Bonanni B, Peccatori FA. *Support Care Cancer*. 2015 Dec;23(12):3555-62. doi: 10.1007/s00520-015-2726-5. Epub 2015 Apr 11.
- 25) RANK-ligand (RANKL) expression in young breast cancer patients and during pregnancy. Azim HA Jr, Peccatori FA, Brohée S, Branstetter D, Loi S, Viale G, Piccart M, Dougall WC, Pruneri G, Sotiriou C. *Breast Cancer Res*. 2015 Feb 21;17:24. doi: 10.1186/s13058-015-0538-7. Epub 2015 Feb 21.
- 26) Discrepancies between ESMO and NCCN breast cancer guidelines: An appraisal. Zagouri F, Liakou P, Bartsch R, Peccatori FA, Tsigginou A, Dimitrakakis C, Zografos GC, Dimopoulos MA, Azim HA Jr. *Breast*. 2015 Aug;24(4):513-23. doi: 10.1016/j.breast.2015.02.031. Epub 2015 Mar 25. Review.
- 27) Targeted agents for cancer treatment during pregnancy. Lambertini M, Peccatori FA, Azim HA Jr. *Cancer Treat Rev*. 2015 Apr;41(4):301-9. doi: 10.1016/j.ctrv.2015.03.001. Epub 2015 Mar 13. Review.

- 28) Contraception is as important as fertility preservation in young women with cancer. Han SN, Van Peer S, Peccatori F, Gziri MM, Amant F; International Network on Cancer, Infertility and Pregnancy. *Lancet*. 2015 Feb 7;385(9967):508. doi: 10.1016/S0140-6736(15)60201-X. No abstract available. PMID:25705843
- 29) Strategies for fertility preservation in young early breast cancer patients. Tomasi-Cont N, Lambertini M, Hulsbosch S, Peccatori AF, Amant F. *Breast*. 2014 Oct;23(5):503-10. doi: 10.1016/j.breast.2014.05.024. Epub 2014 Jun 13.
- 30) Tumour infiltrating lymphocytes (TILs) in breast cancer during pregnancy. Azim HA Jr, Vingiani A, Peccatori F, Viale G, Loi S, Pruneri G. *Breast*. 2015 Jun;24(3):290-3. doi: 10.1016/j.breast.2015.01.009. Epub 2015 Feb 18.
- 31) Pregnancy after breast cancer: Are young patients willing to participate in clinical studies? Pagani O, Ruggeri M, Manunta S, Saunders C, Peccatori F, Cardoso F, Kaufman B, Paluch-Shimon S, Gewefel H, Gallerani E, Abulkhair OM, Pistilli B, Warner E, Saloustros E, Perey L, Zaman K, Rabaglio M, Gelber S, Gelber RD, Goldhirsch A, Korde L, Azim HA Jr, Partridge AH. *Breast*. 2015 Jun;24(3):201-7. doi: 10.1016/j.breast.2015.01.005. Epub 2015 Feb 4.
- 32) Cancer of unknown primary during pregnancy: an exceptionally rare coexistence. Pavlidis N, Peccatori F, Lofts F, Greco AF. *Anticancer Res*. 2015 Jan;35(1):575-9. Review.
- 33) Locoregional treatment of breast cancer during pregnancy. Toesca A, Gentilini O, Peccatori F, Azim HA Jr, Amant F. *Gynecol Surg*. 2014;11(4):279-284. Epub 2014 Sep 30. Review.
- 34) Risk of thrombosis in women with malignancies undergoing ovarian stimulation for fertility preservation. Somigliana E, Peccatori FA, Filippi F, Martinelli F, Raspagliesi F, Martinelli I. *Hum Reprod Update*. 2014 Nov-Dec;20(6):944-51. doi: 10.1093/humupd/dmu035. Epub 2014 Jul 10.
- 35) Treatment options for pregnant women with ovarian tumors. Mancari R, Tomasi-Cont N, Sarno MA, Azim HA Jr, Franchi D, Carinelli S, Biglia N, Colombo N, Peccatori FA. *Int J Gynecol Cancer*. 2014 Jul;24(6):967-72. doi: 10.1097/IGC.000000000000161. Review.
- 36) Fertility preservation in cancer patients: the global framework. Linkeviciute A, Boniolo G, Chiavari L, Peccatori FA. *Cancer Treat Rev*. 2014 Sep;40(8):1019-27. doi: 10.1016/j.ctrv.2014.06.001. Epub 2014 Jun 11. Review.
- 37) Patient-centred management in idiopathic pulmonary fibrosis: similar themes in three communication models. Wuyts WA, Peccatori FA, Russell AM. *Eur Respir Rev*. 2014 Jun;23(132):231-8. doi: 10.1183/09059180.00001614. Review.
- 38) Biology of breast cancer during pregnancy using genomic profiling. Azim HA Jr, Brohée S, Peccatori FA, Desmedt C, Loi S, Lambrechts D, Dell'Orto P, Majjaj S, Jose V, Rotmensz N, Ignatiadis M, Pruneri G, Piccart M, Viale G, Sotiriou C. *Endocr Relat Cancer*. 2014 Aug;21(4):545-54. doi: 10.1530/ERC-14-0111. Epub 2014 May 13.
- 39) First international consensus guidelines for breast cancer in young women (BCY1). Partridge AH, Pagani O, Abulkhair O, Aebi S, Amant F, Azim HA Jr, Costa A, Delaloge S, Freilich G, Gentilini OD, Harbeck N, Kelly CM, Loibl S, Meiorow D, Peccatori F, Kaufmann B, Cardoso F. *Breast*. 2014 Jun;23(3):209-20. doi: 10.1016/j.breast.2014.03.011. Epub 2014 Apr 24.

- 40) Whole-body magnetic resonance imaging, metastatic breast cancer and pregnancy: a case report. Montagna E, Peccatori F, Petralia G, Tomasi Cont N, Iorfida M, Colleoni M. *Breast*. 2014 Jun;23(3):295-6. doi: 10.1016/j.breast.2014.01.012. Epub 2014 Feb 13. No abstract available.
- 41) Locked-in syndrome after basilar artery thrombosis by mucormycosis masquerading as meningoencephalitis in a lymphoma patient. Maffini F, Coccorocchio E, Pruneri G, Bonomo G, Peccatori F, Chiapparini L, Vincenzo SD, Martinelli G, Viale G. *Ecancermedicalscience*. 2013 Dec 19;7:382. doi: 10.3332/ecancer.2013.382. eCollection 2013.
- 42) Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in cancer women: systematic review and meta-analysis of randomized trials. Del Mastro L, Ceppi M, Poggio F, Bighin C, Peccatori F, Demeestere I, Levaggi A, Giraudi S, Lambertini M, D'Alonzo A, Canavese G, Pronzato P, Bruzzi P. *Cancer Treat Rev*. 2014 Jun;40(5):675-83. doi: 10.1016/j.ctrv.2013.12.001. Epub 2013 Dec 8. Review.
- 43) Lung cancer in pregnancy: report of nine cases from an international collaborative study. Boussios S, Han SN, Fruscio R, Halaska MJ, Ottevanger PB, Peccatori FA, Koubkova L, Pavlidis N, Amant F. *Lung Cancer*. 2013 Dec;82(3):499-505. doi: 10.1016/j.lungcan.2013.09.002. Epub 2013 Sep 12.
- 44) Reply to Z. Blumenfeld et al. Demeestere I, Brice P, Peccatori FA, Kentos A, Gaillard I, Zachee P, Casasnovas O, Van Den Neste E, Dechene J, De Maertelaer V, Bron D, Englert Y. *J Clin Oncol*. 2013 Oct 10;31(29):3722-3. doi: 10.1200/JCO.2013.50.7129. Epub 2013 Sep 3.
- 45) Immediate breast reconstruction with expander in pregnant breast cancer patients. Lohsiriwat V, Peccatori FA, Martella S, Azim HA Jr, Sarno MA, Galimberti V, De Lorenzi F, Intra M, Sangalli C, Rotmensz N, Pruneri G, Renne G, Schorr MC, Nevola Teixeira LF, Rietjens M, Giroda M, Gentilini O. *Breast*. 2013 Oct;22(5):657-60. doi: 10.1016/j.breast.2013.06.005. Epub 2013 Jul 17.
- 46) Are monoclonal antibodies a safe treatment for cancer during pregnancy? Sarno MA, Mancari R, Azim HA Jr, Colombo N, Peccatori FA. *Immunotherapy*. 2013 Jul;5(7):733-41. doi: 10.2217/imt.13.64. Review. Erratum in: *Immunotherapy*. 2013 Oct;5(10):1146.
- 47) Breast cancer in young women - Special Issue. Azim HA Jr, Peccatori FA. *J Thorac Dis*. 2013 Jun;5 Suppl 1:S1. doi: 10.3978/j.issn.2072-1439.2013.06.16. No abstract available.
- 48) Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Peccatori FA, Azim HA Jr, Orecchia R, Hoekstra HJ, Pavlidis N, Kesic V, Pentheroudakis G; ESMO Guidelines Working Group. *Ann Oncol*. 2013 Oct;24 Suppl 6:vi160-70. doi: 10.1093/annonc/mdt199. Epub 2013 Jun 27.
- 49) Obstetrical, fetal and postnatal effects of gestational antineoplastic chemotherapy: how to counsel cancer patients. Del Pup L, Peccatori FA, Azim HA Jr, Michieli M, Muioli M, Giorda G, Tirelli U, Berretta M. *Int J Immunopathol Pharmacol*. 2012 Apr-Jun;25(2 Suppl):33S-46S. Review.
- 50) Antineoplastic treatment of haematological malignancies during pregnancy: a crucial decision. Michieli M, Peccatori FA, Lleshi A, Del Pup L, Valente D, Rupolo M, Tirelli U, Berretta M. *Int J Immunopathol Pharmacol*. 2012 Apr-Jun;25(2 Suppl):21S-32S. Review.
- 51) Chemotherapy, targeted agents, antiemetics and growth-factors in human milk: how should we counsel cancer patients about breastfeeding? Pistilli B, Bellettini G, Giovannetti E, Codacci-Pisanelli G,

Azim HA Jr, Benedetti G, Sarno MA, Peccatori FA. *Cancer Treat Rev.* 2013 May;39(3):207-11. doi: 10.1016/j.ctrv.2012.10.002. Epub 2012 Nov 28. Review.

52) Cancer in pregnancy: a survey of current clinical practice. Han SN, Kesic VI, Van Calsteren K, Petkovic S, Amant F; ESGO 'Cancer in Pregnancy' Task Force. *Eur J Obstet Gynecol Reprod Biol.* 2013 Mar;167(1):18-23. doi: 10.1016/j.ejogrb.2012.10.026. Epub 2012 Nov 19.

53) Prognostic impact of pregnancy after breast cancer according to estrogen receptor status: a multicenter retrospective study. Azim HA Jr, Kroman N, Paesmans M, Gelber S, Rotmensz N, Ameye L, De Mattos-Arruda L, Pistilli B, Pinto A, Jensen MB, Cordoba O, de Azambuja E, Goldhirsch A, Piccart MJ, Peccatori FA. *J Clin Oncol.* 2013 Jan 1;31(1):73-9. doi: 10.1200/JCO.2012.44.2285. Epub 2012 Nov 19.

54) Gonadotropin-releasing hormone agonist for the prevention of chemotherapy-induced ovarian failure in patients with lymphoma: 1-year follow-up of a prospective randomized trial. Demeestere I, Brice P, Peccatori FA, Kentos A, Gaillard I, Zachee P, Casasnovas RO, Van Den Neste E, Dechene J, De Maertelaer V, Bron D, Englert Y. *J Clin Oncol.* 2013 Mar 1;31(7):903-9. doi: 10.1200/JCO.2012.42.8185. Epub 2012 Nov 5.

55) Fertility preservation in female cancer patients. Demeestere I, Basso O, Moffa F, Peccatori F, Poirot C, Shalom-Paz E. *Obstet Gynecol Int.* 2012;2012:695041. doi: 10.1155/2012/695041. Epub 2012 Oct 20.

56) The European Society of Breast Cancer Specialists recommendations for the management of young women with breast cancer. Cardoso F, Loibl S, Pagani O, Graziottin A, Panizza P, Martincich L, Gentilini O, Peccatori F, Fourquet A, Delaloge S, Marotti L, Penault-Llorca F, Kotti-Kitromilidou AM, Rodger A, Harbeck N; European Society of Breast Cancer Specialists. *Eur J Cancer.* 2012 Dec;48(18):3355-77. doi: 10.1016/j.ejca.2012.10.004. Epub 2012 Oct 29.

57) Fertility Preservation Methods in Breast Cancer. Peccatori FA, Pup LD, Salvagno F, Guido M, Sarno MA, Revelli A, Piane LD, Dolfin E, Franchi D, Molinari E, Immediata V, Chiavari L, Vucetich A, Borini A. *Breast Care (Basel).* 2012 Jun;7(3):197-202. Epub 2012 Jun 27.

58) Prognosis of pregnancy-associated breast cancer: a meta-analysis of 30 studies. Azim HA Jr, Santoro L, Russell-Edu W, Pentheroudakis G, Pavlidis N, Peccatori FA. *Cancer Treat Rev.* 2012 Nov;38(7):834-42. doi: 10.1016/j.ctrv.2012.06.004. Epub 2012 Jul 9. Review.

59) Antibodies against human cytomegalovirus late protein UL94 in the pathogenesis of scleroderma-like skin lesions in chronic graft-versus-host disease. Pastano R, Dell'Agnola C, Bason C, Gigli F, Rabascio C, Puccetti A, Tinazzi E, Cetto G, Peccatori F, Martinelli G, Lunardi C. *Int Immunol.* 2012 Sep;24(9):583-91. doi: 10.1093/intimm/dxs061. Epub 2012 Jul 6.

60) High-dose chemotherapy in relapsed or refractory Hodgkin lymphoma patients: a reappraisal of prognostic factors. Cocorocchio E, Peccatori F, Vanazzi A, Piperno G, Calabrese L, Botteri E, Travaini L, Preda L, Martinelli G. *Hematol Oncol.* 2013 Mar;31(1):34-40. doi: 10.1002/hon.2014. Epub 2012 Mar 30.

61) Pregnant with metastatic neuroendocrine tumour of the ovary: what now? Pistilli B, Grana C, Fazio N, Cavaliere A, Ferrari M, Bodei L, Baio S, Scambia G, Paganelli G, Peccatori F. *Ecancermedicalscience.* 2012;6:240. doi: 10.3332/ecancer.2012.240. Epub 2012 Jan 3.

- 62) Managing pregnant women with cancer: personal considerations and a review of the literature. Azim H Jr, Gentilini O, Locatelli M, Ciriello E, Scarfone G, Peccatori F. *Ecancermedalscience*. 2011;5:204. doi: 10.3332/ecancer.2011.204. Epub 2011 Feb 14.
- 63) "The only thing I know is that I know nothing": 5-fluorouracil in human milk. Peccatori FA, Giovannetti E, Pistilli B, Bellettini G, Codacci-Pisanelli G, Losekoot N, Curigliano G, Azim HA Jr, Goldhirsch A, Peters GJ. *Ann Oncol*. 2012 Feb;23(2):543-4. doi: 10.1093/annonc/mdr582.
- 64) Optimizing the use of epidermal growth factor receptor inhibitors in advanced non-small-lung cancer (NSCLC). Shash E, Peccatori FA, Azim HA Jr. *J Thorac Dis*. 2011 Mar;3(1):57-64. doi: 10.3978/j.issn.2072-1439.2010.12.05.
- 65) Multiple approaches for individualized fertility protective therapy in cancer patients. Demeestere I, Moffa F, Peccatori F, Poirot C, Shalom-Paz E. *Obstet Gynecol Int*. 2012;2012:961232. doi: 10.1155/2012/961232. Epub 2011 Dec 29.
- 66) The biological features and prognosis of breast cancer diagnosed during pregnancy: a case-control study. Azim HA Jr, Botteri E, Renne G, Dell'orto P, Rotmensz N, Gentilini O, Sangalli C, Pruneri G, Di Nubila B, Locatelli M, Sotiriou C, Piccart M, Goldhirsch A, Viale G, Peccatori FA. *Acta Oncol*. 2012 May;51(5):653-61. doi: 10.3109/0284186X.2011.636069. Epub 2011 Dec 16.
- 67) Breast ductal carcinoma and metastatic lymphoma to the contralateral breast in patient with cutaneous non-Hodgkin lymphoma. Di Nubila B, Meroni S, Bonello L, Peccatori F, Cassano E, Bellomi M. *Hippokratia*. 2011 Jan;15(1):84-6.
- 68) Fatherhood during imatinib. Shash E, Bassi S, Cocorocchio E, Colpi GM, Cinieri S, Peccatori FA. *Acta Oncol*. 2011 Jun;50(5):734-5. doi: 10.3109/0284186X.2011.577562. Epub 2011 Apr 26.
- 69) Managing cancer during pregnancy: what evidence do we have? Azim HA Jr, Peccatori FA. *Pol Arch Med Wewn*. 2011 Jan-Feb;121(1-2):29-34. Review.
- 70) Motherhood after breast cancer: searching for la dolce vita. Azim HA Jr, Peccatori FA, de Azambuja E, Piccart MJ. *Expert Rev Anticancer Ther*. 2011 Feb;11(2):287-98. doi: 10.1586/era.10.208. Review.
- 71) Rituximab in Hodgkin lymphoma: is the target always a hit? Saini KS, Azim HA Jr, Cocorocchio E, Vanazzi A, Saini ML, Raviele PR, Pruneri G, Peccatori FA. *Cancer Treat Rev*. 2011 Aug;37(5):385-90. doi: 10.1016/j.ctrv.2010.11.005. Epub 2010 Dec 22. Review.
- 72) Treatment of breast cancer during pregnancy: regimen selection, pregnancy monitoring and more... Azim HA Jr, Del Mastro L, Scarfone G, Peccatori FA. *Breast*. 2011 Feb;20(1):1-6. doi: 10.1016/j.breast.2010.10.008. Epub 2010 Dec 15. Review.
- 73) The impact of histopathologic examination of graft-versus-host disease in the era of reduced-intensity conditioning regimen: a study from the Gruppo Italiano Trapianto di Midollo Osseo. Massi D, Fondi C, Nozzoli C, Benemei S, Lapi F, Albarello L, Avellini C, Bonoldi E, Casini M, Cesinaro AM, Ciceri F, Colombetti V, Comin CE, Donelli A, Fortunato M, Fratoni S, Guidi S, Messerini L, Milone G, Rapezzi D, Negri G, Patriarca F, Peccatori FA, Ponzoni M, Rafaniello P, Raimondi R, Salomone E, Tendas A, Villari L, Santucci M, Bosi A. *Hum Pathol*. 2011 Feb;42(2):254-68. doi: 10.1016/j.humpath.2010.07.004. Epub 2010 Nov 24.

- 74) Breastfeeding in breast cancer survivors: pattern, behaviour and effect on breast cancer outcome. Azim HA Jr, Bellettini G, Liptrott SJ, Armeni ME, Dell'Acqua V, Torti F, Di Nubila B, Galimberti V, Peccatori F. *Breast*. 2010 Dec;19(6):527-31. doi: 10.1016/j.breast.2010.05.018.
- 75) Treatment of cancer during pregnancy with monoclonal antibodies: a real challenge. Azim HA Jr, Azim H, Peccatori FA. *Expert Rev Clin Immunol*. 2010 Nov;6(6):821-6. doi: 10.1586/eci.10.77. No abstract available.
- 76) Safety of pregnancy following breast cancer diagnosis: a meta-analysis of 14 studies. Azim HA Jr, Santoro L, Pavlidis N, Gelber S, Kroman N, Azim H, Peccatori FA. *Eur J Cancer*. 2011 Jan;47(1):74-83. doi: 10.1016/j.ejca.2010.09.007. Epub 2010 Oct 11. Review.
- 77) Breast cancer in pregnancy: recommendations of an international consensus meeting. Amant F, Deckers S, Van Calsteren K, Loibl S, Halaska M, Brepoels L, Beijnen J, Cardoso F, Gentilini O, Lagae L, Mir O, Neven P, Ottevanger N, Pans S, Peccatori F, Rouzier R, Senn HJ, Struikmans H, Christiaens MR, Cameron D, Du Bois A. *Eur J Cancer*. 2010 Dec;46(18):3158-68. doi: 10.1016/j.ejca.2010.09.010.
- 78) Treatment of cancer during pregnancy: the need for tailored strategies. Azim HA Jr, Peccatori FA. *J Clin Oncol*. 2010 Jun 20;28(18):e302-3; author reply e304. doi: 10.1200/JCO.2010.28.0628. Epub 2010 May 10. No abstract available.
- 79) Intensified CHLVP/ABVVP chemotherapy regimen and pegfilgrastim support in advanced Hodgkin lymphoma. Cocorocchio E, Vanazzi A, Bassi S, Peccatori F, Antoniotti P, Gigli F, Travaini L, Piperno G, Pruneri G, Preda L, Biffi R, Botteri E, Negri M, Martinelli G. *Ecancermedicalscience*. 2010;4:184. doi: 10.3332/ecancer.2010.184. Epub 2010 Sep 8.
- 80) Treatment of the pregnant mother with cancer: a systematic review on the use of cytotoxic, endocrine, targeted agents and immunotherapy during pregnancy. Part II: Hematological tumors. Azim HA Jr, Pavlidis N, Peccatori FA. *Cancer Treat Rev*. 2010 Apr;36(2):110-21. doi: 10.1016/j.ctrv.2009.11.004. Epub 2009 Dec 16. Review.
- 81) Treatment of the pregnant mother with cancer: a systematic review on the use of cytotoxic, endocrine, targeted agents and immunotherapy during pregnancy. Part I: Solid tumors. Azim HA Jr, Peccatori FA, Pavlidis N. *Cancer Treat Rev*. 2010 Apr;36(2):101-9. doi: 10.1016/j.ctrv.2009.11.007. Epub 2009 Dec 16. Review.
- 82) Lung cancer in the pregnant woman: to treat or not to treat, that is the question. Azim HA Jr, Peccatori FA, Pavlidis N. *Lung Cancer*. 2010 Mar;67(3):251-6. doi: 10.1016/j.lungcan.2009.10.006. Epub 2009 Nov 5. Review.
- 83) Have we reached a plateau in adjuvant breast cancer therapy? Codacci-Pisanelli G, Spinelli GP, Peccatori FA. *Lancet*. 2009 Oct 24;374(9699):1421. doi: 10.1016/S0140-6736(09)61862-6.
- 84) Pregnancy in breast cancer survivors: a need for proper counseling. Peccatori FA, Azim HA Jr. *Breast*. 2009 Dec;18(6):337-8. doi: 10.1016/j.breast.2009.09.014. Epub 2009 Oct 9.
- 85) Sentinel lymph node biopsy in pregnant patients with breast cancer. Gentilini O, Cremonesi M, Toesca A, Colombo N, Peccatori F, Sironi R, Sangalli C, Rotmensz N, Pedroli G, Viale G, Veronesi P,

Galimberti V, Goldhirsch A, Veronesi U, Paganelli G. *Eur J Nucl Med Mol Imaging*. 2010 Jan;37(1):78-83. doi: 10.1007/s00259-009-1217-7.

86) GnRH analogue for chemotherapy-induced ovarian damage: too early to say? Peccatori F, Demeestere I. *Fertil Steril*. 2009 Aug;92(2):e33; author reply e34. doi: 10.1016/j.fertnstert.2009.06.002.

87) Management of anaplastic large-cell lymphoma during pregnancy. Peccatori FA, Azim HA Jr, Pruneri G, Piperno G, Raviele PR, Preda L, Ciocca M, Orecchia R, Martinelli G. *J Clin Oncol*. 2009 Sep 1;27(25):e75-7. doi: 10.1200/JCO.2009.22.2042. Epub 2009 Jun 8.

88) Breast cancer and pregnancy: how safe is trastuzumab? Azim HA Jr, Peccatori FA, Liptrott SJ, Catania C, Goldhirsch A. *Nat Rev Clin Oncol*. 2009 Jun;6(6):367-70. doi: 10.1038/nrclinonc.2009.48.

89) The effect of endocrine responsiveness on high-risk breast cancer treated with dose-intensive chemotherapy: results of International Breast Cancer Study Group Trial 15-95 after prolonged follow-up. Colleoni M, Sun Z, Martinelli G, Basser RL, Coates AS, Gelber RD, Green MD, Peccatori F, Cinieri S, Aebi S, Viale G, Price KN, Goldhirsch A; International Breast Cancer Study Group. *Ann Oncol*. 2009 Aug;20(8):1344-51. doi: 10.1093/annonc/mdp024. Epub 2009 May 25.

90) Carboplatin and weekly paclitaxel for the treatment of advanced non-small cell lung cancer (NSCLC) during pregnancy. Azim HA Jr, Scarfone G, Peccatori FA. *J Thorac Oncol*. 2009 Apr;4(4):559-60. doi: 10.1097/JTO.0b013e31819c8674. No abstract available.

91) Communication skills and raising awareness in clinical practice: an Italian experience. Liptrott S, Peccatori F, Cocquio A, Martinelli G. *Ecancermedicalsecience*. 2009;3:135. doi: 10.3332/ecancer.2009.135. Epub 2009 Feb 11.

92) Safety of pregnancy following breast cancer diagnosis. Peccatori FA, Azim HA Jr. *Acta Oncol*. 2009;48(3):470-1; author reply 471. doi: 10.1080/02841860802546792. No abstract available.

93) Rituximab in lymphocyte-predominant Hodgkin disease. Azim HA Jr, Pruneri G, Coccorocchio E, Cinieri S, Raviele PR, Bassi S, Preda L, Martinelli G, Peccatori FA. *Oncology*. 2009;76(1):26-9. doi: 10.1159/000177953. Epub 2008 Nov 24.

94) Procalcitonin as a useful marker of infection in hemato-oncological patients with fever. Sandri MT, Passerini R, Leon ME, Peccatori FA, Zorzino L, Salvatici M, Riggio D, Cassatella C, Cinieri S, Martinelli G. *Anticancer Res*. 2008 Sep-Oct;28(5B):3061-5.

95) Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93. Pagani O, Gelber S, Simoncini E, Castiglione-Gertsch M, Price KN, Gelber RD, Holmberg SB, Crivellari D, Collins J, Lindtner J, Thürlimann B, Fey MF, Murray E, Forbes JF, Coates AS, Goldhirsch A; International Breast Cancer Study Group. *Breast Cancer Res Treat*. 2009 Aug;116(3):491-500. doi: 10.1007/s10549-008-0225-9. Epub 2008 Oct 25.

96) Is electron beam intraoperative radiotherapy (ELIOT) safe in pregnant women with early breast cancer? In vivo dosimetry to assess fetal dose. Galimberti V, Ciocca M, Leonardi MC, Zanagnolo V, Paola B, Manuela S, Sahium RC, Lazzari R, Gentilini O, Peccatori F, Veronesi U, Orecchia R. *Ann Surg Oncol*. 2009 Jan;16(1):100-5. doi: 10.1245/s10434-008-0172-z. Epub 2008 Oct 21.

- 97) Weekly epirubicin in the treatment of gestational breast cancer (GBC). Peccatori FA, Azim HA Jr, Scarfone G, Gadducci A, Bonazzi C, Gentilini O, Galimberti V, Intra M, Locatelli M, Acaia B, Rossi P, Cinieri S, Calabrese L, Goldhirsch A. *Breast Cancer Res Treat.* 2009 Jun;115(3):591-4. doi: 10.1007/s10549-008-0159-2. Epub 2008 Aug 20.
- 98) Extramedullary myeloid sarcoma of the breast. Azim HA Jr, Gigli F, Pruneri G, Martinelli G, Travaini LL, Petralia G, Peccatori FA. *J Clin Oncol.* 2008 Aug 20;26(24):4041-3. doi: 10.1200/JCO.2008.17.3997. No abstract available. Erratum in: *J Clin Oncol.* 2008 Oct 20;26(30):5003.
- 99) Circulating endothelial cell number and viability are reduced by exposure to high altitude. Mancuso P, Peccatori F, Rocca A, Calleri A, Antoniotti P, Rabascio C, Saronni L, Zorzino L, Sandri MT, Zubani A, Bertolini F. *Endothelium.* 2008 Jan-Feb;15(1):53-8. doi: 10.1080/10623320802092344.
- 100) Anthracyclines for gestational breast cancer: course and outcome of pregnancy. Azim HA Jr, Peccatori FA, Scarfone G, Acaia B, Rossi P, Cascio R, Goldhirsch A. *Ann Oncol.* 2008 Aug;19(8):1511-2. doi: 10.1093/annonc/mdn396. Epub 2008 Jun 18.
- 101) Treatment of metastatic breast cancer during pregnancy: we need to talk! Azim HA Jr, Peccatori FA. *Breast.* 2008 Aug;17(4):426-8. doi: 10.1016/j.breast.2008.02.005. Epub 2008 May 2.
- 102) Breast-feeding after breast cancer: if you wish, madam. Azim HA Jr, Bellettini G, Gelber S, Peccatori FA. *Breast Cancer Res Treat.* 2009 Mar;114(1):7-12. doi: 10.1007/s10549-008-9983-7. Epub 2008 Mar 29. Review.
- 103) p27 and Skp2 immunoreactivity and its clinical significance with endocrine and chemo-endocrine treatments in node-negative early breast cancer. Ravaioli A, Monti F, Regan MM, Maffini F, Mastropasqua MG, Spataro V, Castiglione-Gertsch M, Panzini I, Gianni L, Goldhirsch A, Coates A, Price KN, Gusterson BA, Viale G; International Breast Cancer Study Group. *Ann Oncol.* 2008 Apr;19(4):660-8. doi: 10.1093/annonc/mdm547. Epub 2008 Feb 13.
- 104) Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93. Thürlimann B, Price KN, Gelber RD, Holmberg SB, Crivellari D, Colleoni M, Collins J, Forbes JF, Castiglione-Gertsch M, Coates AS, Goldhirsch A; International Breast Cancer Study Group. *Breast Cancer Res Treat.* 2009 Jan;113(1):137-44. doi: 10.1007/s10549-008-9912-9. Epub 2008 Feb 8.
- 105) Subsequent pregnancy after breast cancer. Peccatori F, Cinieri S, Orlando L, Bellettini G. *Recent Results Cancer Res.* 2008;178:57-67. Review. No abstract available.
- 106) Why is the topic of cancer and pregnancy so important? Why and how to read this book. Surbone A, Peccatori F, Pavlidis N. *Recent Results Cancer Res.* 2008;178:1-2. No abstract available.
- 107) ERCC1 Expression in Diffuse Large B-Cell Lymphoma Patients Treated with a Cisplatin-Based Regimen : A Brief Communication. Azim HA Jr, Pruneri G, Raviele PR, Steffanoni S, Martinelli G, Peccatori FA. *J Egypt Natl Canc Inst.* 2007 Sep;19(3):176-7.
- 108) Unmet needs of cancer survivors: supportive care's new challenge. Surbone A, Peccatori FA. *Support Care Cancer.* 2006 May;14(5):397-9. Epub 2006 Apr 8. No abstract available.
- 109) Multicycle dose-intensive chemotherapy for women with high-risk primary breast cancer: results of International Breast Cancer Study Group Trial 15-95.

International Breast Cancer Study Group, Basser RL, O'Neill A, Martinelli G, Green MD, Peccatori F, Cinieri S, Coates AS, Gelber RD, Aebi S, Castiglione-Gertsch M, Viale G, Price KN, Goldhirsch A.
J Clin Oncol. 2006 Jan 20;24(3):370-8.

110) Mediastinal-like growing teratoma syndrome.

D'Aiuto M, Veronesi G, Peccatori FA, Pelosi G, Venturino M, Gasparri R, Presicci F, Galetta D, Spaggiari L.
J Thorac Cardiovasc Surg. 2005 Jul;130(1):228-9. No abstract available.

111) Breast cancer diagnosed during pregnancy and lactation: biological features and treatment options.
Gentilini O, Masullo M, Rotmensz N, Peccatori F, Mazzarol G, Smeets A, Simsek S, De Dosso S, Veronesi P, Intra M, Zurrada S, Viale G, Goldhirsch A, Veronesi U.
Eur J Surg Oncol. 2005 Apr;31(3):232-6.

112) Unusual cases in multiple myeloma and a dramatic response in metastatic lung cancer: Case 2.
Plasma cell myeloma coexisting with metastatic breast carcinoma in the bone marrow.
Pruneri G, Cinieri S, Peccatori F, Viale G.
J Clin Oncol. 2005 Jan 1;23(1):232-3. No abstract available.

113) Autologous peripheral blood stem cell transplantation for myocardial regeneration: a novel strategy for cell collection and surgical injection.
Pompilio G, Cannata A, Peccatori F, Bertolini F, Nascimbene A, Capogrossi MC, Biglioli P.
Ann Thorac Surg. 2004 Nov;78(5):1808-12.

114) Mammaglobin expression in leukapheresis products is a predictive marker of poor prognosis in women with high-risk breast cancer.
Ferrucci PF, Rabascio C, Mazzetta C, Cocorocchio E, Agazzi A, Vanazzi A, Cinieri S, Peccatori FA, Paolucci M, Bertolini F, Martinelli G.
Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6039-46.

115) Chemotherapy during pregnancy: what is really safe?
Peccatori F, Martinelli G, Gentilini O, Goldhirsch A.
Lancet Oncol. 2004 Jul;5(7):398. No abstract available.

116) Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy.
Cardinale D, Sandri MT, Colombo A, Colombo N, Boeri M, Lamantia G, Civelli M, Peccatori F, Martinelli G, Fiorentini C, Cipolla CM.
Circulation. 2004 Jun 8;109(22):2749-54. Epub 2004 May 17.

117) ChlVPP/ABVVP, a first line 'hybrid' combination chemotherapy for advanced Hodgkin's lymphoma: a retrospective analysis.
Martinelli G, Cocorocchio E, Peccatori F, Zucca E, Saletti PC, Calabrese L, Pastano R, Pruneri G, Mazzetta C, Ghielmini M, Cavalli F.
Br J Haematol. 2004 Jun;125(5):584-9.

118) Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule.
Ghielmini M, Schmitz SF, Cogliatti SB, Pichert G, Hummerjohann J, Waltzer U, Fey MF, Betticher DC, Martinelli G, Peccatori F, Hess U, Zucca E, Stupp R, Kovacsics T, Helg C, Lohri A, Bargetzi M, Vorobiof D, Cerny T.
Blood. 2004 Jun 15;103(12):4416-23. Epub 2004 Feb 19.

119) Phase IB and pharmacological study of the novel taxane BMS-184476 in combination with doxorubicin.
Sessa C, Perotti A, Salvatorelli E, Minotti G, Viganò L, Lladò A, Capri G, Locatelli A, Colombini S, Peccatori F, Voi M, Marsoni S, Gianni L.
Eur J Cancer. 2004 Mar;40(4):563-70.

120) Efficacy of vinblastine, bleomycin, methotrexate (VBM) combination chemotherapy with involved field radiotherapy in early stage (I-IIA) Hodgkin disease patients.

Martinelli G, Cocorocchio E, Saletti PC, Orecchia R, Bernier J, Tradati N, Santoro P, Robertson C, Peccatori FA, Zucca E, Cavalli F.
Leuk Lymphoma. 2003 Nov;44(11):1919-23. Review.

121) Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type.
Conconi A, Martinelli G, Thiéblemont C, Ferreri AJ, Devizzi L, Peccatori F, Ponzoni M, Pedrinis E, Dell'Oro S, Pruneri G, Filipazzi V, Dietrich PY, Gianni AM, Coiffier B, Cavalli F, Zucca E.
Blood. 2003 Oct 15;102(8):2741-5. Epub 2003 Jul 3.

122) ACOD, a modified CHOP regimen for elderly patients with aggressive non-Hodgkin's lymphoma.
Martinelli G, Ferrucci PF, Mingrone W, Cocorocchio E, Conconi A, Peccatori FA, De Luzio K, Santoro P, Mazzetta C, Zucca E, Cavalli F.
Leuk Lymphoma. 2003 May;44(5):801-6. Erratum in: Leuk Lymphoma. 2003 Jul;44(7):1265.

123) Short- and long-term safety of the 2×10^6 CD34+ cells/kg threshold for hematopoietic reconstitution after high-dose chemotherapy and peripheral blood progenitor cell support.
Corsini C, Bertolini F, Mancuso P, Cinieri S, Peccatori F, Martinelli G.
Ann Oncol. 2002 Jun;13(6):983-5. No abstract available.

124) Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers.
Bertolini F, Mingrone W, Alietti A, Ferrucci PF, Cocorocchio E, Peccatori F, Cinieri S, Mancuso P, Corsini C, Burlini A, Zucca E, Martinelli G.
Ann Oncol. 2001 Jul;12(7):987-90. Erratum in: Ann Oncol 2001 Sep;12(9):1333. Cinieri S [corrected to Cinieri S].

125) Clinical and pharmacological phase I study with accelerated titration design of a daily times five schedule of BBR3464, a novel cationic triplatinum complex.
Sessa C, Capri G, Gianni L, Peccatori F, Grasselli G, Bauer J, Zucchetti M, Viganò L, Gatti A, Minoia C, Liati P, Van den Bosch S, Bernareggi A, Camboni G, Marsoni S.
Ann Oncol. 2000 Aug;11(8):977-83.

126) Human myeloid and lymphoid malignancies in the non-obese diabetic/severe combined immunodeficiency mouse model: frequency of apoptotic cells in solid tumors and efficiency and speed of engraftment correlate with vascular endothelial growth factor production.
Fusetti L, Pruneri G, Gobbi A, Rabascio C, Carboni N, Peccatori F, Martinelli G, Bertolini F.
Cancer Res. 2000 May 1;60(9):2527-34.

127) Acute vulvar vestibulitis occurring during chemotherapy with cryptophycin analogue LY355703.
De Pas TM, Mandalà M, Curigliano G, Peccatori F.
Obstet Gynecol. 2000 Jun;95(6 Pt 2):1030. No abstract available.

128) Evaluation of acute toxicities associated with autologous peripheral blood progenitor cell reinfusion in patients undergoing high-dose chemotherapy.
Ferrucci PF, Martinoni A, Cocorocchio E, Civelli M, Cinieri S, Cardinale D, Peccatori FA, Lamantia G, Agazzi A, Corsini C, Tealdo F, Fiorentini C, Cipolla CM, Martinelli G.
Bone Marrow Transplant. 2000 Jan;25(2):173-7.

129) The absence of swirling in platelet concentrates is highly predictive of poor posttransfusion platelet count increments and increased risk of a transfusion reaction.
Bertolini F, Agazzi A, Peccatori F, Martinelli G, Sandri MT.
Transfusion. 2000 Jan;40(1):121-2. No abstract available.

130) Friedreich's ataxia and intrathecal chemotherapy in a patient with lymphoblastic lymphoma.
De Pas T, Martinelli G, De Braud F, Peccatori F, Catania C, Aapro MS, Goldhirsch A.
Ann Oncol. 1999 Nov;10(11):1393. No abstract available.

131) Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma.
Bertolini F, Paolucci M, Peccatori F, Cinieri S, Agazzi A, Ferrucci PF, Cocorocchio E, Goldhirsch A, Martinelli G.

Br J Haematol. 1999 Aug;106(2):504-9.

132) Totally implantable central venous access ports for high-dose chemotherapy administration and autologous stem cell transplantation: analysis of overall and septic complications in 68 cases using a single type of device.

Biffi R, Martinelli G, Pozzi S, Cinieri S, Cocorocchio E, Peccatori F, Ferrucci PF, Pistorio R, Andreoni B. Bone Marrow Transplant. 1999 Jul;24(1):89-93.

133) ChIVPP/ABV-VP16 hybrid regimen for advanced Hodgkin's disease: a study in 36 patients.

Saletti P, Zucca E, Gueneau M, Peccatori F, Cavalli F, Martinelli G. Leuk Lymphoma. 1999 Apr;33(3-4):313-9.

134) Expression of CD3-zeta on T-cells in primary cervical carcinoma and in metastasis-positive and -negative pelvic lymph nodes.

de Gruijl TD, Bontkes HJ, Peccatori F, Gallee MP, Helmerhorst TJ, Verheijen RH, Aarbiou J, Mulder WM, Walboomers JM, Meijer CJ, van de Vange N, Scheper RJ. Br J Cancer. 1999 Mar;79(7-8):1127-32.

135) Hematopoietic progenitor cell collection and neoplastic cell contamination in breast cancer patients receiving chemotherapy plus granulocyte-colony stimulating factor (G-CSF) or G-CSF alone for mobilization.

Bertolini F, Lanza A, Peccatori F, Zibera C, Gibelli N, Perotti C, Da Prada GA, Torretta L, Cocorocchio E, Martinelli G, Robustelli della Cuna G. Ann Oncol. 1998 Aug;9(8):913-6.

136) Clinical manifestation of severe hyperammonaemia in patients with multiple myeloma.

Martinelli G, Peccatori F, Ullrich B, Ghielmini M, Roggero E, Goldhirsch A. Ann Oncol. 1997 Aug;8(8):811. No abstract available.

137) Comparative effects of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor after high-dose cyclophosphamide cancer therapy.

Bregni M, Siena S, Di Nicola M, Doderio A, Peccatori F, Ravagnani F, Danesini G, Laffranchi A, Bonadonna G, Gianni AM. J Clin Oncol. 1996 Feb;14(2):628-35.

138) Surgical management of malignant ovarian germ-cell tumors: 10 years' experience of 129 patients.

Peccatori F, Bonazzi C, Chiari S, Landoni F, Colombo N, Mangioni C. Obstet Gynecol. 1995 Sep;86(3):367-72.

139) Durability of hematopoiesis following autografting with peripheral blood hematopoietic progenitors.

Siena S, Bregni M, Di Nicola M, Ravagani F, Peccatori F, Gandola L, Lombardi F, Tarella C, Bonadonna G, Gianni AM. Ann Oncol. 1994 Dec;5(10):935-41.

140) Pure ovarian immature teratoma, a unique and curable disease: 10 years' experience of 32 prospectively treated patients.

Bonazzi C, Peccatori F, Colombo N, Lucchini V, Cantù MG, Mangioni C. Obstet Gynecol. 1994 Oct;84(4):598-604.

141) Quantization of CD34+ peripheral blood hematopoietic progenitors for autografting in cancer patients.

Di Nicola M, Siena S, Bregni M, Peccatori F, Magni M, Ravagnani F, Zorzino L, Bonadonna G, Gianni AM. Int J Artif Organs. 1993 Dec;16 Suppl 5:80-2.

142) High-dose sequential chemo-radiotherapy with peripheral blood progenitor cell support for relapsed or refractory Hodgkin's disease--a 6-year update.

Gianni AM, Siena S, Bregni M, Lombardi F, Gandola L, Di Nicola M, Magni M, Peccatori F, Valagussa P, Bonadonna G. Ann Oncol. 1993 Dec;4(10):889-91.

143) Recombinant human interleukin-3 hastens trilineage hematopoietic recovery following high-dose (7 g/m²) cyclophosphamide cancer therapy.
Gianni AM, Siena S, Bregni M, Di Nicola M, Peccatori F, Magni M, Ravagnani F, Sklenar I, Bonadonna G.
Ann Oncol. 1993 Nov;4(9):759-66.

144) Clinical implications of the heterogeneity of hematopoietic progenitors elicited in peripheral blood by anticancer therapy with cyclophosphamide and cytokine(s).
Siena S, Bregni M, Bonsi L, Strippoli P, Peccatori F, Magni M, Di Nicola M, Bagnara GP, Massimo Gianni A.
Stem Cells. 1993 Jul;11 Suppl 2:72-5. Review.

145) Primary ovarian small cell carcinoma: four more cases.
Peccatori F, Bonazzi C, Lucchini V, Bratina G, Mangioni C.
Gynecol Oncol. 1993 Apr;49(1):95-9.

146) Anti-tumor and immunomodulatory activity of intraperitoneal IFN-gamma in ovarian carcinoma patients with minimal residual tumor after chemotherapy.
Colombo N, Peccatori F, Paganin C, Bini S, Brandely M, Mangioni C, Mantovani A, Allavena P.
Int J Cancer. 1992 Apr 22;51(1):42-6.

147) Malignant behavior and resistance to cisplatin of human ovarian carcinoma xenografts established from the same patient at different stages of the disease.
Masazza G, Lucchini V, Tomasoni A, Peccatori F, Lampasona V, Giudici G, Mangioni C, Biondi A, Giavazzi R.
Cancer Res. 1991 Dec 1;51(23 Pt 1):6358-62.

148) Intraperitoneal recombinant gamma-interferon in patients with recurrent ascitic ovarian carcinoma: modulation of cytotoxicity and cytokine production in tumor-associated effectors and of major histocompatibility antigen expression on tumor cells.
Allavena P, Peccatori F, Maggioni D, Erroi A, Sironi M, Colombo N, Lissoni A, Galazka A, Meiers W, Mangioni C, et al.
Cancer Res. 1990 Nov 15;50(22):7318-23.

149) Killing of tumor cells with pleiotropic drug resistance by OK432-activated effector cells.
Allavena P, Peccatori F, Maggioni D, Pirovano P, Mantovani A.
Immunopharmacol Immunotoxicol. 1989;11(2-3):257-68.

150) Lymphocytes infiltrating ovarian carcinoma: modulation of functional activity by intraperitoneal treatment with biological response modifiers.
Allavena P, Peri G, Di Bello M, Peccatori F, Chiaffarino F, Pirovano P, Mantovani A.
Nat Immun Cell Growth Regul. 1988;7(4):230-8. Review.

151) T-cell receptor gene rearrangements and expression in normal human large granular lymphocytes (LGL) and their pathological expansions.
Pirelli A, Allavena P, Rambaldi A, Di Bello M, Pirovano P, Peccatori F, Mantovani A.
Cytotechnology. 1987 Oct;1(1):79-81. doi: 10.1007/BF00351128.

Data

10 AGOSTO 2016

Luogo

MILANO

Federico A. Peccatori